Shares of Annovis Bio Inc. (ANVS) slipped nearly 6% on Tuesday morning despite the company reporting that Buntanetap was found safe and effective in high-risk Alzheimer's patients.
ANVS is currently trading at $6.13, down $0.37 or 5.69%, on the Nasdaq. The stock opened its trading at $6.20 after closing Monday at $6.50. The stock has traded between $4.79 and $22.49 in the past 52-week period.
Annovis Bio, a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), announces that its recent Phase II/III Alzheimer's study of its lead drug candidate, Buntanetap, showed statistically significant efficacy and safety in both carriers and non-carriers of Apolipoprotein E4 (APOE4), a genetic cause of AD.
In patients with early AD, Buntanetap showed a statistically significant dose-response in ADAS-Cog11 scores, with a -3.3 points improvement over baseline and -2.3 points improvement from placebo.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.